Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer.....

Primary tabs

field_vote: 
Average: 7.5 (2 votes)
Publication type: 
Number of included patients: 
References: 
Disease(s): 
Therapeutic Substance(s): 

Impressive survival data with semimetronomic oral chemotherapy
with old agents in heavily treated metastatic breast cancer patients.


Sub-category: Metastatic Breast Cancer
Category: Breast Cancer--Metastatic Breast Cancer
Meeting: 2009 ASCO Annual Meeting
 
Citation: J Clin Oncol 27:15s, 2009 (suppl; abstr 1082)
Abstract No: 1082
Author(s): H. Mutlu,
H. Bozcuk, M. Ozdogan, M. Artac, H. S. Coskun, A. Kargi, M. Uysal, B.
Savas; Akdeniz University School of Medicine, Antalya, Turkey; Selcuk
UniversIty Meram School of Medicine, Konya, Turkey
 
Abstract:
Background:
To assess the efficacy of semi-metronomic regimen metronomic
cyclophosphomide with oral etoposide in heavily treated patients with
metastatic breast cancer.
 
Methods: Consecutive metastatic
breast cancer (MBC) patients predominantly refractory to antracyclines,
taxanes, and antimetabolites receiving semi-metronomic regimen of
metronomic cyclophosphomide with oral etoposide were evaluated for
clinical efficacy and toxicity. This novel regimen comprised of
continuous oral cyclophosphomide 50 mg/day, and oral etoposide given as
2 x 50 mg/day for 5 days every third week.
 
Results: A total of 42 MBC patients
received this treatment in 2.5 years (May 2005-October 2008). The
median age was 51.5 (29-81), ER and/or PR receptor status was positive
in 67%, and c-erb-B2 overexpression existed in 50%. The biologically
favorable group, hormone responsive and c-erb-B2 negative comprised of
36% of cases. The portions of patients with visceral metastases,
cranial metastases, and 2 or more organ involvement were 82%, 24%, and
65%, respectively. Subjects had received this treatment in the fourth
or more advanced setting in 50% of cases (after a median of 2.5
cycles). The median overall and progression free survival figures were
25 and 10.5 months, respectively. No toxic mortality occurred, and the
treatment was well tolerated. Toxicity and response data are being
updated currently.
Conclusion: Semi-metronomic treatment with
metronomic cyclophosphomide and oral etoposide is a novel and effective
strategy in heavily pretreated MBC patients. Survival data and low cost
may make this regimen a highly preferable option in this difficult
patient group.